Wilms Tumor 1 (WT1) Peptide Vaccine

Property	Information
Drug Name	Wilms Tumor Peptide Vaccine
FDA Approval	Not FDA-approved; available at University Hospital of Heidelberg, Germany
Used for	Wilms Tumor, glioblastoma, and other cancers expressing WT1 antigen
Clinical Trial Phase	Phase 3
Clinical Trial Explanation	Not specified
Common Side Effects	Injection site reactions, fatigue, mild fever, allergic reactions (rare)
OS without	Varies depending on stage and treatment; typical survival rates for favorable histology are around 90% for localized disease
OS with	Median OS not reached for the vaccine group vs. 22.2 months for the placebo group; HR: 0.55 (95% CI: 0.35-0.87), p = 0.011
PFS without	Varies depending on stage and treatment
PFS with	Median DFS of 11.9 months for the vaccine group vs. 5.6 months for the placebo group; HR: 0.52 (95% CI: 0.33-0.82), p = 0.005
Usefulness Rating	4
Usefulness Explanation	Shows promise based on significant improvements in overall survival and disease-free survival in high-risk AML patients; ongoing research needed to fully establish efficacy in other cancers
Toxicity Level	2
Toxicity Explanation	Generally well-tolerated with few serious adverse events; typical side effects are mild

Links: https://pubmed.ncbi.nlm.nih.gov/30500939/, https://www.cancertherapyadvisor.com/home/cancer-topics/pediatric-cancer/wilms-tumor-pediatric/peptide-vaccine-treatment/, https://healthcare-in-europe.com/en/news/new-actively-personalized-therapeutic-vaccine-for-brain-cancer.html

From Ben Williams Book: Wilms tumor peptide vaccines represent an emerging treatment modality in the field of oncology. These vaccines aim to stimulate the immune system to target and destroy tumor cells by presenting specific tumor-associated antigens. The University Hospital of Heidelberg in Germany offers this vaccine on a paid basis to patients with Wilms tumor and other cancers expressing the WT1 antigen.

Developed to provide an alternative treatment option, this vaccine has shown promising results in clinical trials, significantly improving overall survival and disease-free survival in high-risk AML patients. Common side effects are generally mild and include injection site reactions, fatigue, and mild fever. Comprehensive long-term data are still being collected, and patients are advised to consult with their oncologist before proceeding.

For more detailed information on the clinical trials and results, refer to the links provided.Property "Has original text" (as page type) with input value "Wilms tumor peptide vaccines represent an emerging treatment modality in the field of oncology. These vaccines aim to stimulate the immune system to target and destroy tumor cells by presenting specific tumor-associated antigens. The University Hospital of Heidelberg in Germany offers this vaccine on a paid basis to patients with Wilms tumor and other cancers expressing the WT1 antigen.</br></br>Developed to provide an alternative treatment option, this vaccine has shown promising results in clinical trials, significantly improving overall survival and disease-free survival in high-risk AML patients. Common side effects are generally mild and include injection site reactions, fatigue, and mild fever. Comprehensive long-term data are still being collected, and patients are advised to consult with their oncologist before proceeding.</br></br>For more detailed information on the clinical trials and results, refer to the links provided." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.

Loading comments...